Realizing Benefits of First‐in‐Class Generic Entry—The Case of SGLT2 Inhibitors

Dr. Gondi reported employment at Health Strategy. Dr. Kesselheim and Dr. Rome reported receiving grants from the Elevance Health Public Policy Institute, Humana, and the PCMA Foundation and personal fees from Alosa Health outside the submitted work. Dr. Kesselheim also reports serving as an expert witness on behalf of a payor in a case against Teva regarding marketing of Copaxone and on behalf of a group of state attorneys general and payors in a case against multiple generic manufacturers related to alleged price fixing.